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EVALUATION OF THE EFFECT OF ADDING CORTICOSTEROID TO
VISCOSUPPLEMENTATION: A PROSPECTIVE AND RANDOMIZED STUDY
G.C. Campos, M.U. Rezende, A.F. Pailo, R. Frucchi, T. Pasqualin. IOT - FMUSP,
São Paulo, Brazil
Purpose: The aim of this study is to assess if we can improve the initial
results of viscosupplementation by the addition of corticosteroids to the
procedure, watching for any interference on the long-term results.
Methods:We evaluated 104 patients with knee osteoarthritis (OA), treated
at the group for the treatment of osteometabolic diseases of IOT-FMUSP,
São Paulo. All patients were receiving usual care for OA, and those who
underwent to any kind of intraarticular injection or knee surgery in the last
6 months, or presented post-traumatic or rheumatoid arthritis were not
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Results
SCORE WEEK MEAN (Group 1) SD (Group 1) Conﬁdence interval (95%) N (Gr
WOMAC 0 50,21 16,15 45,71 - 54,71 52
WOMAC 1 45,83 18,52 40,67 - 50,98 52
WOMAC 4 39,00 17,87 33,97 - 44,03 51
WOMAC 12 34,48 19,25 28,76 - 40,19 46
WOMAC 24 36,72 19,05 31,06 - 42,37 46
VAS 0 67,27 20,08 61,68 - 72,86 52
VAS 1 55,29 26,52 47,91 - 62,67 52
VAS 4 50,41 24,10 43,63 - 57,19 51
VAS 12 46,22 26,18 38,44 - 53,99 46
VAS 24 49,41 21,94 42,74 - 56,08 44
LEQUESNE 0 13,24 3,85 12,17 - 14,31 52
LEQUESNE 1 11,86 4,05 10,74 - 12,99 52
LEQUESNE 4 10,96 4,13 9,80 - 12,12 51
LEQUESNE 24 10,32 4,27 9,02 - 11,62 44included into the protocol. We applied the visual analogic scale of pain
(VAS) and the algofunctional questionnaires WOMAC and Lequesne.
Patients were randomized into two groups of 52 patients each. Group 1
received a single intraarticular injection of the knee with 6ml of Synvisc
One (Hylan GF-20) alone. Patients in group 2 received an intraarticular
injection of the knee with 6ml of Synvisc One (Hylan GF-20) and 1ml
(20mg) of Hexacetonide Triamcinolone. The questionnaires were applied
prior to the injection (week zero) and at weeks 1, 4, 12 and 24 after the
procedure.
This study was aproved by the University of São Paulo Clinics Hospital's
ethics committee and entirely funded by FAPESP (Cientiﬁc research
support foundation) - Grant number 2010/11450-9. It can be accessed at
clinicaltrials.com.
Results: The patient's characteristics of the two groups were compared
with chi-square and Fisher's exact tests and were considered homogeneus.
Most patiens were female (76%). The mean age was 62,7 years old. The
average BMI of patients was 29.52. Most patients (34,6%) had a level 3
Kellgreen and Lawrence radiological classiﬁcation for knee OA.
The pre-injection scores were:
Group 1- WOMAC ¼ 50,21 (SD ¼ 16,15); VAS ¼ 67,27 (SD ¼ 20,08);
Lequesne ¼ 13.24 (SD ¼ 3,85).
Group 2- WOMAC ¼ 54,54 (SD ¼ 17,58); VAS ¼ 70,21 (SD ¼ 23,59);
Lequesne ¼ 13.86 (SD ¼ 4,18). These results were statistically compared
and there was no statistic difference between groups.
At Week 1, Group 2 showed a marked reduction for WOMAC and VAS
scores, with a statistically signiﬁcant difference compared with week zero
and also when compared with Group 1 week one results. At week 4, group
2 still had better results for WOMAC and VAS compared to group 1, but
with a p>0,05.
TheWOMAC and VAS results for weeks 12 and 24were similar within the 2
groups.
The Lequesne results had no statistically signiﬁcant difference between the
2 groups at any moment. However, each group had a statistically signiﬁ-
cant improvement at weeks 1, 4, 12 and 24 compared to the baseline.
Results are shown in tables and graphics below:oup 1) MEAN (Group 2) SD (Group 2) Conﬁdence interval (95%) N (Group 2)
54,54 17,58 49,65 - 59,43 52
34,38 20,04 28,81 - 39,96 52
31,75 17,58 26,86 - 36,64 52
36,43 16,50 31,58 - 41,27 47
38,11 16,72 33,20 - 43,01 47
70,21 23,59 63,64 - 76,78 52
38,52 24,65 31,66 - 45,38 52
37,40 25,24 30,38 - 44,43 51
46,70 23,51 39,71 - 53,68 47
50,15 23,46 43,26 - 57,04 47
13,86 4,18 12,69 - 15,02 52
10,93 4,73 9,61 - 12,25 52
9,70 4,12 8,55 - 10,85 52








1 week 0 vs week 1 1,38 -0,15 - 2,90 0,117
1 week 0 vs week 4 2,22 0,25 - 4,18 0,014
1 week 0 vs week 12 3,38 1,14 - 5,63 <0,001
1 week 0 vs week 24 2,80 0,38 - 5,21 0,010
2 week 0 vs week 1 2,92 1,40 - 4,45 <0,001
2 week 0 vs week 4 4,15 2,20 - 6,11 <0,001
2 week 0 vs week 12 2,84 0,60 - 5,08 0,003
2 week 0 vs week 24 2,27 -0,11 - 4,66 0,076
WEEK 0 Group 1 vs Group 2 -0,62 -3,16 - 1,93 0,999
WEEK 1 Group 1 vs Group 2 0,93 -1,62 - 3,48 0,977
WEEK 4 Group 1 vs Group 2 1,32 -1,23 - 3,88 0,824
WEEK 12 Group 1 vs Group 2 -1,16 -3,80 - 1,48 0,927
WEEK 24 Group 1 vs Group 2 -1,14 -3,83 - 1,55 0,942







1 week 0 vs week 1 11,98 1,67 - 22,29 0,009
1 week 0 vs week 4 17,03 4,26 - 29,81 0,001
1 week 0 vs week 12 21,17 7,00 - 35,34 <0,001
1 week 0 vs week 24 17,39 2,47 - 32,30 0,009
2 week 0 vs week 1 31,69 21,38 - 42,00 <0,001
2 week 0 vs week 4 32,81 20,10 - 45,52 <0,001
2 week 0 vs week 12 23,30 9,14 - 37,46 <0,001
2 week 0 vs week 24 19,87 5,16 - q 34,57 0,001
WEEK 0 Group 1 vs Group 2 -2,94 -17,82 - 11,94 >0,999
WEEK 1 Group 1 vs Group 2 16,77 1,89 - 31,65 0,014
WEEK 4 Group 1 vs Group 2 12,83 -2,10 - 27,77 0,164
WEEK 12 Group 1 vs Group 2 -0,81 -16,38 - 14,75 >0,999








1 week 0 vs week 1 4,38 -2,23 - 11,00 0,52
1 week 0 vs week 4 11,46 2,93 - 19,99 0,001
1 week 0 vs week 12 15,56 5,79 - 25,32 <0,001
1 week 0 vs week 24 13,38 2,94 - 23,82 0,002
2 week 0 vs week 1 20,15 13,54 - 26,77 <0,001
2 week 0 vs week 4 22,79 14,30 - 31,28 <0,001
2 week 0 vs week 12 17,08 7,37 - 26,78 <0,001
2 week 0 vs week 24 15,76 5,39 - 26,14 <0,001
WEEK 0 group 1 vs group 2 -4,33 -15,45 - 6,80 0,966
WEEK 1 group 1 vs group 2 11,44 0,32 - 22,56 0,038
WEEK 4 group 1 vs group 2 7,00 -4,16 - 18,15 0,602
WEEK 12 group 1 vs group 2 -2,81 -14,32 - 8,71 0,999
WEEK 24 group 1 vs group 2 -1,94 -13,60 - 9,71 >0,999ĂNone of the individuals characteristics such as age, genre, BMI or Kell-
green and Lawrence classiﬁcation had any effects on the results. Adverse
effects were: 4,8% of the patients presented effusion and 19,2% of the
patients related discomfort or pain. There was no statistic difference
between the groups.
Conclusion: We concluded that the addition of 1ml of triancinolone to
viscosupplementation brings great improvement to its early results and
does not affect the long-term results, so it should be performed.<br
336
MUSCLE STRENGTH AND MUSCLE MASS ONE YEAR AFTER AN INITIAL 16
WEEK INTENSE WEIGHT LOSS: A RANDOMIZED CONTROLLED TRIAL
J. Aaboe 1, H. Bliddal 1, B. Danneskiold-Samsøe 1, P. Christensen 1,
R. Christensen 1,2, M. Henriksen 1. 1 The Parker Inst., Frederiksberg, Denmark;
2 Inst. of Sports Sci. and Clinical Biomechanics, Faculty of Hlth.Sci., Univ. of
Southern Denmark, Odense, Denmark
Purpose: Knee osteoarthritis (OA) and muscle weakness often coexist and
lower muscle strength and less muscle mass pose possible detrimental
effects on physical function and changed muscle metabolism. In obese OA
patients this is particularly important because reductions in muscle
strength and leanmass are known as unsolicited side effects of weight loss.
Thus, participation in exercise regimens followingweight loss is advocated
in the clinic to maintain muscle strength and lean mass. The purpose of
this study was to investigate the effect of a one year exercise treatment
following an intense weight loss compared to dietary counselling or no
attention (control) on leg muscle strength and lean mass.
Methods: A population of obese patients above 50 years of age with knee
OA (ACR criteria) was included in an intense 16 weeks weight loss inter-
vention (NCT NCT00655941). After weight loss, patients were randomized
to one of three groups; a supervised/home based Exercise program,
continuous Dietary support, or a no attention Control group for one year.
The exercise programme consisted of 3 training sessions/week, gradually
translating the intervention from facility based exercises to home based
sessions. At baseline (pre weight loss) and 1 year post weight loss (68
weeks) patients had their body composition analyzed using dual energy X-
ray absorptiometry (DXA) scans together with isometric knee muscle
strength and a self reported symptomatic outcome score (KOOS). The
average of 4 out of the 5 KOOS subscales, excluding sports and recreation
subscale, were used. Changes from baseline to one year follow-up were
compared between groups using analysis of covariance (ANCOVA) with
a factor for group, adjusting for baseline values of the outcome measure.
Results: 171 patients (80% females), 62.7 years of age and BMI 37.3 kg/m2
were included, which at baseline had complete DXA scan and muscle
strength data. The randomization procedure on this “Muscle strength
subsample” resulted in 59, 57 and 55 patients in groups C, D and E,
respectively. After 1 year, 145 patients (85% of baseline) completed the
study (Table 1). Group E did not achieve a statistically signiﬁcant greater
increase in muscle strength compared to Group D and Group C (Table 2).
Similar results were found for lean body mass and KOOS4 (Table 2). While
Group E achieved a lower loss of total body weight (MD: D vs. E; -4.8 kg [CI
